Wave Life Sciences股价上涨,因其减肥药进入联合用药试验

路透中文
Sep 23
BUZZ-<a href="https://laohu8.com/S/WVE">Wave Life</a> Sciences股价上涨,因其减肥药进入联合用药试验

9月23日 - ** 药物开发商Wave Life Sciences(WVE.O)的股价在盘前交易中上涨1.4%,至4.41美元

** 该公司已开始对其试验性减肥药物WVE-007与制药公司礼来(LLY.N)的每周一次减肥及糖尿病注射剂tirzepatide联合使用的中期临床试验

** WVE-007是一种基于RNA的治疗药物,旨在促进脂肪减少的同时保持肌肉量,且每年仅需给药一至两次

** 该试验将针对肥胖和2型糖尿病患者,测试240毫克和400毫克剂量的WVE-007

** 在动物研究中,WVE-007与GLP-1药物联合使用,其减重效果是单独使用GLP-1治疗的两倍——WVE

** 该公司仍按计划将于2026年下半年启动另一项临床试验,以验证WVE-007能否在患者停止肠促胰素类药物治疗后抑制体重反弹

** 截至上一交易日收盘,WVE今年以来累计下跌74.4%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10